Synribo (omacetaxine mepesuccinate) Injection is an FDA-approve drug use for the treatment of leukemia. The drug is only available through a valid prescription. The drug is also only available in certain countries. If you want to buy it, you need a prescription and you can visit your doctor or the nearest pharmacy.
SYNRIBO OMACETAXINE MEPESUCCINATE INJECTION
Synribo (omacetaxine mepesuccinate) Injection is an antineoplastic product that is approve for the treatment of leukemia. The recommend dose of SYNRIBO is one milligram per m2 subcutaneously give twice daily at approximately twelve-hour interval. Patients should use this medicine only after obtaining a valid prescription.
Because of the risk of accidental injection or ingestion of SYNRIBO, it must be handle with care. Always wear protective eyewear and gloves. Ensure that you are using the correct aseptic technique and that any contact with SYNRIBO is completely wash
SYNRIBO OMACETAXINATE INJECTION in India should be administer only by a healthcare professional. It should not be handle or store with food or drinks. Additionally pregnant women and children should not receive this drug. In addition, patients should ensure that the medication is administer in a clean environment and that the injection site is free from wounds, bruises, or other conditions.
SYNRIBO OMACETAXINE MEPESUCCINATE INJECTION Price
Synribo Injection is a targeted therapy drug for adult patients with leukemia. It is a subcutaneous injection use to treat the disease. It is only available with a valid prescription and is available in certain countries.
Synribo is an injectable medication develop by Teva Oncology, a subsidiary of Teva Pharmaceutical Industries. It is use for treating chronic myeloid leukemia, a type of white blood cell cancer. Currently unapprove in many countries, but has been approve in the U.S. since 2012.
Synribo is a protein synthesis inhibitor, intended for subcutaneous administration. Its mechanism of action is independent of Bcr-Abl binding. Therefore, it can be use in patients with advanced CML who are not responding to two tyrosine kinase inhibitors.